Exactech Announces First Total Ankle Surgeries in South America

Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced first surgeries in Latin America with the Vantage® Total Ankle Fixed Bearing System.

Manuel Pellegrini, MD, and Giovanni Carcuro, MD, of the Clinica Universidad de los Andes, performed the bilateral ankle procedures in Chile earlier this month.

“Many patients worldwide are benefitting from the Vantage Ankle, and I’m honored to be the first to use it on my continent,” said Dr. Pellegrini. “My patient not only received one, but two Exactech implants, and I look forward to seeing their progress post-surgery.”

The Vantage Ankle was first launched in the U.S. in 2016 and received clearance in Chile earlier this year. It is designed to recreate the natural biomechanics of the ankle joint through its curved talus component, which aligns with the talus’ trabecular bone structure, and tibial implant. Specifically, the press-fit tibial component is designed for anatomic cortical coverage and fibular articulation and features a center bone cage and three plasma pegs that are engineered to create initial fixation.1 In addition, the system features a polyethylene liner and a unique locking clip for secure fastening of the polyethylene liner.

“We are thrilled to be part of this landmark procedure,” said Foot and Ankle Marketing Director Devan Carter. “The Vantage Ankle has helped many patients get back to what they love doing, and we’re happy to share these clinical results with patients and surgeons in Chile. We hope to expand into other Latin American countries in the future.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.